Assetmark Inc. Acquires 28,701 Shares of Gilead Sciences, Inc. $GILD

2026-02-19 06:46:20

Assetmark Inc. increased its stake in Gilead Sciences, Inc. by 22.5% in the third quarter, purchasing an additional 28,701 shares, bringing its total holdings to 156,118 shares valued at $17,329,000. Other institutional investors have also made significant changes to their positions in the biopharmaceutical company. Analysts have maintained a “Moderate Buy” consensus rating and a target price of $152.50 for GILD, following positive Q4 earnings, raised FY26 guidance, and pipeline catalysts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.